Catumaxomab
As of the edition of 20 October 2026, Catumaxomab is an antibody: marketed, first approved in 2025 (EU); acts on CD3D, CD3E and CD3G and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody
- Brand name
- Korjuny
- First approved
- 10 February 2025 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Atnahs Pharma
- Withdrawn from market
- 2 June 2017 (in some regions)
- Registered trials
- 15, 2 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Hormones; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Catumaxomab.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 1 |
| Phase 2 | 11 | 9 | 0 | 1 |
| Phase 3 | 2 | 1 | 0 | 0 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Atnahs Pharma | Applicant | 2025 to now |